Some studies have already investigated the blockade of TIGIT, LAG-3/GAL-3 pathway, resulting in reduction of exhausted T cells, immune activation, and MM-cell cytolysis, and leading to potentially new strategies that could be explored in future clinical trials [57,68,69,70]. This evidence concerns the gene LAG3 and Miyoshi myopathy.